Vertical AI Agents for Biopharma
Automated discovery, diligence and in‑licensing of drug assets at global scale
BIOPTIC® AI agents triage, assess, and prioritize drug assets worldwide, fusing molecular insight, clinical evidence, and deal economics into a single AI-driven decision engine.
Automate pipeline development. Surface undervalued assets in any language. Scale scientific and business diligence 103×.
Scanning 100+ language sources
Uncovering undervalued drug assets worldwide: from SEC filings to Chinese patents
Integrated AI Agents
Asset Scouting
Scans every paper, filing and news source in every language worldwide to surface and cluster deal opportunities.
In-Licensing
Ranks best‑fit external assets, drafts term sheets and automates outreach.
Due Diligence
Assembles red‑flag memos from trial data, patents, and competitive intel in hours.
Commercialization
Sizes markets, models pricing & access, builds launch scenarios.
Proprietary Scientific Models
B1
Ligand-based model. The fastest way of screening 100B compound libraries.
Predicts potency, safety, and manufacturability for any compound in seconds, already fueling a robust pipeline of drug candidates.
B2
Sequence-based model. Predicts binders for novel targets.
Identifies potent, selective compounds (< 0.4 Tanimoto) with 4-8% wet‑lab validated hit rates.
B3
Universal ADMET predictor.
Delivers rapid, full-profile ADME/Tox predictions to flag liabilities early.
Platform
Precision search
Pinpoint by indication, target, modality or molecule with clean, fully referenced results.
Zero hallucinations
Benchmark-proven multi-agent QA with in-house checks, citations, and numeric plot audits.
Curated data stack
Only high-quality, licensed sources: SEC filings, FDA guidelines, trials, market and media feeds.
Reinforcement loop
Continuous improvement through regular RLHF retraining that incorporates user queries and human feedback.
Autonomous monitoring
Agents track trials, patents, licensing deals, and regulatory shifts in real time.
BIOPTIC vs ChatGPT
BIOPTIC®
ChatGPT
Proprietary data:
Ligand, Assay, Clinical
Yes
No
No hallucinations:
Multi-agent QA and numeric plot checks
Yes
No
Scientific accuracy:
Wet-lab and PLINDER validation
Yes
No
Built-in tools integration:
CADD and ADME/Tox
Yes
No
Workflow integration:
Science-to-deal intelligence
Yes
No
Real-time:
Pipeline / deal monitoring
Yes
Limited
Autonomy
High
Low
Traceability
Full
None
Pricing
Predictable
Usage-based
Mechanica Partners
Venture creation firm that builds and funds a new generation of biotechnology companies.
"Our early work with OPTIC’s B1 and B2 models showed real promise in integrating AI into drug discovery. We look forward to seeing how the BIOPTIC agentic AI platform will further connect our scientific discoveries to strategic business insights, providing a powerful edge in our venture creation strategy"
— James Sietstra, Founder and General Partner at Mechanica Partners
Request a demo
Schedule a 30 minute demo to see BIOPTIC® AI agents surface qualified assets for your focus area.
Company
Founded by former Google executives, our team unites AI researchers, life scientists, and biopharma strategy experts with backgrounds across pharma, tech, academia and consulting.
